{'fraction_non_alphanumeric': 0.014989293361884369, 'fraction_numerical': 0.0, 'mean_word_length': 5.493055555555555, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Photodynamic therapy and urothelial carcinoma].

PURPOSE
Photodynamic therapy (PDT) is an innovative therapeutic modality in urologic oncology.


MATERIAL AND METHODS
We reviewed the current literature on principles and modalities of PDT in urothelial and penile oncology.


RESULTS
PDT has been tested for the treatment recurrent superficial bladder tumors and in situ carcinoma. Carcinologic efficacy has been observed with first generation photosensitizer. The lack of selectivity for tumoral cells was responsible of serious adverse events. Development of selective photosensitizers has reduced the importance of side effects. Data concerning PDT for upper urinary tract and urethra carcinoma are still limited.


CONCLUSION
First PDT clinical applications in urothelial oncology have shown some effectiveness at the cost of significant morbidity. The development of selective photosensitizers should help to reduce side effects.